Back to User profile » Dr Benedict
Paper published by Dr Benedict:
Original Research
![Noteworthy comment: Survival and best supportive care costs for patients with metastatic renal cell carcinoma (mRCC) after stopping therapy are poorly characterized yet an important aspect of patient care. This study examined survival and costs associated with BSC after 1 or 2 lines of mRCC therapy](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population
Henk HJ, Chen C, Benedict A, Sullivan J, Teitelbaum A
ClinicoEconomics and Outcomes Research 2013, 5:347-354
Published Date: 9 July 2013